z-logo
open-access-imgOpen Access
Oedema‐based model for diffuse low‐grade gliomas: application to clinical cases under radiotherapy
Author(s) -
Badoual M.,
Gerin C.,
Deroulers C.,
Grammaticos B.,
Llitjos J.F.,
Oppenheim C.,
Varlet P.,
Pallud J.
Publication year - 2014
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/cpr.12114
Subject(s) - radiation therapy , medicine , population , growth model , surgery , mathematics , environmental health , mathematical economics
Objectives Diffuse low‐grade gliomas are characterized by slow growth. Despite appropriate treatment, they change inexorably into more aggressive forms, jeopardizing the patient's life. Optimizing treatments, for example with the use of mathematical modelling, could help to prevent tumour regrowth and anaplastic transformation. Here, we present a model of the effect of radiotherapy on such tumours. Our objective is to explain observed delay of tumour regrowth following radiotherapy and to predict its duration. Materials and methods We have used a migration–proliferation model complemented by an equation describing appearance and draining of oedema. The model has been applied to clinical data of tumour radius over time, for a population of 28 patients. Results We were able to show that draining of oedema accounts for regrowth delay after radiotherapy and have been able to fit the clinical data in a robust way. The model predicts strong correlation between high proliferation coefficient and low progression‐free gain of lifetime, due to radiotherapy among the patients, in agreement with clinical studies. We argue that, with reasonable assumptions, it is possible to predict (precision ~20%) regrowth delay after radiotherapy and the gain of lifetime due to radiotherapy. Conclusions Our oedema‐based model provides an early estimation of individual duration of tumour response to radiotherapy and thus, opens the door to the possibility of personalized medicine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here